Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Do grow up Baz-Kingsy. Long term holders are doing very well - my average is a bit over £7, and the current low price is an opportunity to top up (which I probably won't take, as the NG rights issue has taken most of my recently available cash). Despite puerile conspiracy theorists, "MMs" are incapable of manipulating the share price, up or down. Just because you lost a little in the (very) short term, doesn't make everybody else corrupt, just that you timed your investment poorly.
Back to £18 by year end, thanks to the Wall St primary listing.
Further drop to under £13.
Fishy fishy fishy!
Where did they mention dividends? I’d much rather them keep doing buybacks.
Supposedly, it’s down because of FTSE250 expulsion. US investors won’t give 2 figs whether it’s in the FTSE250 or not.
The drift lower this far ahead of US listing will be fund(s) positioning to benefit from the strong upward momentum that will come nearer the date. Once US listing takes effect I expect that INDV will not last that long before being taken out by big pharma.
I also note the comments made by INDV Directors during call following the recent results that referred to dividends. I think that share buy-backs will be replaced by dividends going forward.
Given the US market trades at higher multiples than the UK market, and indivior is moving the primary listing to the US, will this have a positive impact on price?
The stock keeps trading lower when revenues are growing and analyst are upgrading the target price. Looks to me UK investors trying to get out before the listing in June and think liquidity.
Any view?
Seems like it's 1 step forward and 2 steps back over the last month. Need alot of patience when investing in this due lots of manipulation in share price.
I am staying in till i see the share price starts with 2
Thanks for the clarificaton idk
That’s operating profit (EBIT). Subtract taxes to get net income for PE.
Looks like expected P/E for 2024 around 7 using low end profit estimate.
134,887,108 shares (from todays "Transaction in Own Shares" RNS)
Low end profit $330M
Projected EPS 2.45 USD
SP 13.66 GBP
so 17.36 USD using ex-rate 1.27113
So P/E ~7.1
Less if profits higher.
(More if they get fined again... Fingers crossed they don't !!!)
Very strong SP move after this update. This together with upcoming primary listing move to USA should be major catalysts over the coming weeks. Share buyback also continuing into August.
GM just confirmed "We expect the transfer of the primary listing will become effective on Thursday June 27, 2024."
Very strong support for this move as one would expect given that the bulk of sales currently comes from USA.
Finally we have some clarity from the Board with full year 2024 guidance reaffirmed and 18% YOY revenues exceeded.
Good swing upwards following the RNS which was delivered at 12:00pm only 30 mins ago.
Let's hope we get back to the 1700s over the next couple of weeks. No justifiable reason it shouldn't.
GLA LTH
Next Thursday when GM takes place. Should be a formality to get approval.
How long before INDV is purchased by big pharma? Also share buyback is due to continue until August 2024.
FTSE 250
Deutsche Bank initiates Indivior with 'buy' - target 2,350 pence
( PLENTY OF UPSIDE EXPECTED HERE)
One has nothing to do with the other.
Interesting that the directors sold shares at £17 and the SP drops to under £14!🤔
I wasn't as energised as I usually am by the presentation. Looks like they're flatlining somewhat. Mitigating factor I guess being the cyber attack which impacted recent revenues. Let's hope that is the reason.
Positives: sublocade still growing and only a small proportion of the market. Sales team fully recruited and resourced so no additional expenses there. They ve got a real foothold now in US market, no doubting that. Dental claim not that big of a deal, reading between the lines. And full steam ahead for shareholder vote next month with view to main US listing in June.
Revenue growth much worse than expected due to those one time factors they mentioned
Excellent quarterly results but unexplainable drop in sp this morning!
...For the three months to March 31, Indivior reported net revenue of USD284 million, up 12% from USD253 million a year prior.
Net income rose 7% to USD47 million from USD44 million, while pretax profit rose 8.6% to USD63 million from USD58 million.
Jefferies raises Indivior price target to 2,390 (2,165) pence - 'buy' (12 March 2024)
More good news!
RICHMOND, Va. - Indivior PLC (LSE/Nasdaq: LON:INDV) has announced the results of a pharmacodynamic study indicating that its drug OPVEE® can quickly reverse opioid-induced respiratory depression, a major cause of death in opioid overdoses. The study, comparing intranasal nalmefene (OPVEE) with intranasal naloxone, was published in the Journal of Clinical Pharmacology.
The study met its primary endpoint by showing that OPVEE reversed respiratory depression within five minutes of administration, while naloxone took 20 minutes to achieve a similar effect. Minute ventilation, a measure of breathing, reached approximately 95% of the pre-opioid baseline within five minutes after OPVEE was administered.
In the study, 69 healthy volunteers experienced a reduction in minute ventilation after being administered remifentanil, a synthetic opioid. They were then treated with either OPVEE or naloxone. OPVEE was found to be non-inferior and superior to naloxone in the speed of reversing opioid-induced respiratory depression.
OPVEE shows rapid reversal of opioid effects in study
OPVEE shows rapid reversal of opioid effects in study
Investing.com | Editor Brando Bricchi
Published Mar 11, 2024 18:52
Be the first to comment
OPVEE shows rapid reversal of opioid effects in study
RICHMOND, Va. - Indivior PLC (LSE/Nasdaq: LON:INDV) has announced the results of a pharmacodynamic study indicating that its drug OPVEE® can quickly reverse opioid-induced respiratory depression, a major cause of death in opioid overdoses. The study, comparing intranasal nalmefene (OPVEE) with intranasal naloxone, was published in the Journal of Clinical Pharmacology.
The study met its primary endpoint by showing that OPVEE reversed respiratory depression within five minutes of administration, while naloxone took 20 minutes to achieve a similar effect. Minute ventilation, a measure of breathing, reached approximately 95% of the pre-opioid baseline within five minutes after OPVEE was administered.
In the study, 69 healthy volunteers experienced a reduction in minute ventilation after being administered remifentanil, a synthetic opioid. They were then treated with either OPVEE or naloxone. OPVEE was found to be non-inferior and superior to naloxone in the speed of reversing opioid-induced respiratory depression.
ADVERTISEMENT
Although adverse events were reported in over 90% of subjects following both drugs, these were mostly mild to moderate and were attributed to the remifentanil and experimental conditions rather than the drugs themselves. Common adverse events included headache, nausea, vomiting, and dizziness.
Get The App
Join the millions of people who stay on top of global financial markets with Investing.com.
Download Now
The urgency for rapid-acting opioid reversal agents is underscored by the high number of opioid overdose deaths, which in the United States totaled over 80,000 in the 12 months ending in September 2023, with synthetic opioid
Article from Investing.com (Published Mar 11, 2024 18:52)
https://uk.investing.com/news/stock-market-news/opvee-shows-rapid-reversal-of-opioid-effects-in-study-93CH-3376280
I will take my prediction back from yesterday as £18 quite possibe today with thus game changing news